Shiyao Innovation (300765.SZ) subsidiary Envequ Madouzhu monoclonal antibody injection application for listing has been accepted.

Chinastock Finance APP news, Shiyao Innovation (300765.SZ) announced that its controlling subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., recently received the "Acceptance Notice" issued by the National Medical Products Administration, and the market application for Enzalutamide Injection was accepted.